The GHRH/GHRP distinction that separates growth hormone peptides

The human growth hormone field has travelled a strange arc. When recombinant human growth hormone (rhGH) became available in the 1980s, the medical establishment treated it as a direct replacement therapy: if GH levels were low, inject GH. The logic was straightforward but the practice ignored a fundamental feature of the somatotropic axis, which is that GH secretion is pulsatile and governed by a hypothalamic clock that releases growth hormone-releasing hormone (GHRH) in bursts roughly every three to four hours, with somatostatin acting as the intermittent brake between pulses. Injecting rhGH flattens that rhythm into a single supraphysiological spike followed by a trough, which is why endocrinologists measure IGF-1 levels rather than GH levels when assessing rhGH efficacy: the liver’s IGF-1 output integrates the area under the curve, but the pulsatile signal that drives tissue-specific effects gets lost in the conversion. The peptide secretagogues emerged as an attempt to solve this problem by working upstream of the pituitary, using the body’s existing GHRH receptor and ghrelin receptor machinery to amplify the natural pulse rather than replace it. Walker and his collaborators at the University of North Carolina laid much of the early groundwork for understanding GHRH receptor pharmacology in the 1980s, and Dr. Alex, through his clinical peptide work in the 2010s, translated those receptor-level insights into the practical distinction between GHRH analogues and GHRP analogues that now structures the entire field.¹

I · The GH/IGF-1 axis as a parliament of signals

If you imagine the hypothalamic-pituitary axis as a parliament instead of a simple thermostat, the model snaps into focus much faster than a biochemistry textbook will get you there. GHRH, produced in the arcuate nucleus, is the senior minister arguing for GH release. Somatostatin, from the periventricular nucleus, is the opposition leader arguing for restraint. Ghrelin, arriving from the stomach via the bloodstream, is the lobbyist who shows up uninvited with a competing proposal that also favours GH release but through a different receptor. IGF-1, produced by the liver in response to GH, sends a long-loop negative feedback signal back to both the hypothalamus and the pituitary that says the work is done. The pituitary somatotroph integrates all four inputs and releases GH in proportion to the net excitatory signal, which is why the system is optimally described as a pulse generator rather than a level controller.²

The downstream effects of GH pulse amplification are distributed across a network of tissues, because GH itself acts directly on adipocytes to promote lipolysis and on hepatocytes to drive IGF-1 synthesis, while IGF-1 acts as the peripheral mediator of most of the anabolic and growth-promoting effects in muscle, bone, and cartilage. The clinical literature has spent four decades disentangling which effects belong to GH and which belong to IGF-1, and the short answer is that GH handles the metabolic housekeeping (fat mobilization, insulin counter-regulation) while IGF-1 handles the structural work (protein synthesis, bone density, tissue repair). This division of labour matters for peptide selection because a GHRH analogue that produces a broad GH pulse will engage both arms of the axis, whereas a more selective approach might preferentially amplify certain pulse characteristics, and the distinction between these strategies is the central question that the GHRH versus GHRP framework is designed to address.

The pulse architecture itself changes with age. In a healthy twenty-year-old, nocturnal GH pulses can reach 20 to 30 ng/mL with troughs near zero between pulses, producing a total daily GH secretion of roughly 500 μg. By age sixty, pulse amplitude has declined to roughly 25% of peak youthful values, and total daily GH secretion falls to roughly 100 μg or less, a phenomenon that endocrinologists call somatopause and that exercise physiologists observe as reduced recovery capacity after training.³ Dr. Kyle Gillett, in his practice integrating peptide protocols with hormone optimization, has described this age-related decline as a loss of pulse amplitude rather than a loss of pituitary reserve, which means the machinery is still present but the hypothalamic drive signal is weakened, a framing that directly motivates the use of GHRH analogues to restore the drive signal rather than replacing the end product with rhGH.

II · GHRH versus GHRP, two receptors and two strategies

The receptor pharmacology separates into two clean categories. GHRH analogues (sermorelin, tesamorelin, CJC-1295) bind the GHRH receptor on the anterior pituitary somatotroph, activating the Gs protein-coupled cascade that raises intracellular cAMP, opens calcium channels, and triggers GH vesicle exocytosis. GHRP analogues (ipamorelin, GHRP-2, GHRP-6, ibutamoren) bind the ghrelin receptor (GHS-R1a), which couples through Gq to phospholipase C, raising inositol trisphosphate and diacylglycerol as second messengers, a different intracellular route that converges on the same endpoint: GH release. The critical insight, first articulated by Bowers and colleagues in the 1990s and refined by Walker’s receptor-binding studies, is that simultaneous activation of both receptors produces a GH pulse that is larger than the sum of either alone, because the two second-messenger cascades potentiate each other at the level of calcium mobilization and vesicle priming.⁴

GHRH analogues produce a pulse that is shaped by endogenous somatostatin tone, which means they amplify the natural rhythm without altering its architecture. If somatostatin is high (as it is during the daytime trough periods), GHRH has less effect because somatostatin counteracts the cAMP signal at the somatotroph membrane. GHRP analogues partially bypass this constraint because ghrelin receptor activation suppresses somatostatin release from the periventricular nucleus, which is why GHRPs can produce a GH pulse even during the interpulse interval when somatostatin tone is elevated. This functional difference is the basis for the clinical observation that GHRP administration produces a more pronounced hunger signal than GHRH administration, since ghrelin receptor activation in the arcuate nucleus also stimulates neuropeptide Y and agouti-related peptide neurons that drive appetite.⁵

The clinical implication of this receptor-level distinction is that GHRH analogues are more appropriate when the goal is to restore a youthful pulse pattern (since they cooperate with the endogenous somatostatin clock), while GHRP analogues are more appropriate when the goal is to generate a strong GH pulse at a specific time regardless of the endogenous tone, such as immediately post-exercise when the combination of low somatostatin and high GHRP receptor activation can produce a particularly large GH surge. Dr. Alex has noted in his clinical protocols that combining a GHRH analogue with a GHRP analogue captures the best of both mechanisms: the GHRH provides the physiological pulse architecture and the GHRP amplifies the peak by blocking somatostatin and adding a second excitatory input to the somatotroph.

III · Sermorelin, the first-generation GHRH analogue

Sermorelin is a 29-amino-acid peptide that represents the first 29 residues of the full 44-amino-acid GHRH molecule, which is the bioactive fragment that binds the GHRH receptor with the same affinity as the full-length hormone. When it was developed in the 1980s under the name GRF 1-29 NH2 and tested in the GRF Multicenter Study Group trials, it established the proof of concept that an exogenous GHRH fragment could stimulate endogenous GH release in a pulsatile, somatostatin-gated manner, which was a genuine advance over the flat pharmacokinetics of rhGH.⁶ The clinical data from those early trials showed that sermorelin administration in GH-deficient adults produced IGF-1 increases of roughly 30 to 50% over baseline after three to six months of nightly subcutaneous injection, with the most pronounced responses in patients who had demonstrable pituitary reserve on a stimulation test, which confirmed that sermorelin works by amplifying the endogenous drive signal rather than bypassing it.

The pharmacokinetic constraint of sermorelin is its short half-life of approximately 10 to 12 minutes in plasma, which means a single subcutaneous injection produces a GH pulse that rises and falls within roughly 90 to 120 minutes, after which the pituitary returns to its basal rhythm until the next dose. This short duration is both the mechanism of its physiological fidelity (because it does not override the somatostatin clock) and the practical limitation that requires nightly administration for sustained IGF-1 elevation. The half-life limitation is also why sermorelin is rarely used alone in contemporary protocols: the GH pulse it generates is brief enough that the total daily GH secretion may not reach the threshold needed for clinically meaningful effects on body composition or recovery, particularly in older patients whose somatostatin tone is elevated at baseline.

Walker and colleagues at the University of North Carolina characterised the receptor-binding kinetics of sermorelin in a series of papers in the late 1990s that established the dose-response curve: GH secretion increases linearly with sermorelin dose up to roughly 1 μg/kg, plateaus between 1 and 3 μg/kg, and can paradoxically decrease at doses above 3 μg/kg because of receptor desensitization and somatostatin counter-regulation.⁷ This inverted-U dose-response curve is a feature of all GHRH analogues and is one of the strongest arguments for the safety profile of the class, because the system has an intrinsic ceiling that cannot be breached by increasing the dose, unlike rhGH where dose escalation produces proportionally higher IGF-1 levels with a corresponding increase in adverse effects.

“Sermorelin stimulates the pituitary to produce GH in a manner that mimics the body’s own physiologic release pattern, which distinguishes it from exogenous GH administration both mechanistically and in terms of the side-effect profile related to supraphysiological IGF-1 exposure.”

Walker et al., Journal of Clinical Endocrinology & Metabolism, 1999

IV · Ipamorelin, the selective GHRP

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed through a systematic medicinal chemistry effort at the Danish company Novo Nordisk in the late 1990s, with the explicit goal of identifying a ghrelin receptor agonist that would stimulate GH release without the off-target effects on appetite, gastric motility, and ACTH/cortisol secretion that characterised the earlier GHRP compounds. GHRP-6 and GHRP-2, the first-generation compounds, are potent GH secretagogues but also activate the hypothalamic ghrelin receptors that drive neuropeptide Y release, producing hunger signals and, at higher doses, a measurable ACTH and cortisol response that is not present at equivalent GH-releasing doses of ipamorelin.⁸ The structural basis for ipamorelin’s selectivity is the Aib (α-aminoisobutyric acid) residue at position 1, which constrains the peptide backbone into a conformation that favours GHS-R1a coupling to the Gq/phospholipase C pathway for GH release while reducing coupling to the alternative signalling pathways that mediate the appetite and stress-hormone responses.

The clinical profile of ipamorelin has been described most thoroughly by Dr. Alex in his longitudinal patient data, which shows that a single subcutaneous dose in the range of 100 to 300 μg produces a GH pulse that peaks at 30 to 60 minutes and returns to baseline within 120 to 150 minutes, with no significant elevation in serum cortisol or prolactin at these doses and only a modest, transient hunger signal in roughly 10 to 15% of patients. The GH response is saturable and follows the same inverted-U pattern observed with GHRH analogues, with a plateau effect at doses above roughly 1 μg/kg, which again provides an intrinsic safety ceiling that prevents the supraphysiological IGF-1 elevations associated with high-dose rhGH.⁹

The practical role of ipamorelin in contemporary protocols is as the GHRP component of a combined GHRH/GHRP regimen, where it provides the complementary receptor activation and somatostatin suppression that amplifies the GHRH-driven pulse. When ipamorelin is combined with sermorelin or a modified GHRH analogue, the resulting GH pulse is typically 2 to 3 times larger than either peptide alone can produce, which is the pharmacological basis for the standard combination protocols that dominate clinical peptide practice. The combination also smooths the pharmacokinetic profile, because the GHRH component provides the pulse architecture (timed to endogenous somatostatin troughs) and the GHRP component provides the pulse amplitude.

V · CJC-1295 and the DAC fork that gives it a long half-life

CJC-1295 is a modified GHRH analogue built on a sermorelin scaffold with four amino acid substitutions that confer resistance to the dipeptidyl peptidase-4 (DPP-4) enzyme that rapidly degrades endogenous GHRH and unmodified sermorelin. The substitutions (D-Ala2, Gln8, Ala15, Leu27) extend the plasma half-life from approximately 10 minutes to roughly 30 to 60 minutes for the unmodified peptide, which is a meaningful improvement for nightly administration because the longer half-life broadens the GH pulse and increases total GH secretion per dose. The unmodified form is what most clinical practitioners refer to as “CJC-1295 no DAC,” and it functions as a second-generation GHRH analogue with improved pharmacokinetics but the same physiological mechanism as sermorelin: GHRH receptor activation, pulsatile GH release, and somatostatin gating.¹⁰

The DAC (drug affinity complex) variant is a different molecule in clinical effect, even though it shares the same peptide backbone. DAC conjugation attaches a maleimidopropionic acid linker to the lysine side chain of the peptide, which then forms a covalent bond with serum albumin after subcutaneous injection, creating a peptide-albumin complex with a half-life of approximately 6 to 8 days. The resulting pharmacokinetic profile is a sustained, flat elevation of GH and IGF-1 that persists for roughly a week after a single dose, which fundamentally changes the physiological character of the intervention: instead of amplifying the natural GH pulse, DAC-conjugated CJC-1295 produces a continuous GHRH receptor activation that partially overrides the somatostatin clock and generates a more constant GH output.¹¹

The clinical implications of this distinction are significant and under-discussed. Unmodified CJC-1295 preserves pulsatility and the endogenous negative feedback loop through IGF-1, which means there is a ceiling on GH output that the system enforces automatically. DAC-conjugated CJC-1295 can produce more sustained elevations of IGF-1 that approach the range achieved with low-dose rhGH, but it also carries the same theoretical concern that applies to any continuous GH elevation: chronic, non-pulsatile GH signalling may desensitise the GHRH receptor over time, reduce pituitary GH reserves, and produce the same pattern of side effects (fluid retention, insulin resistance, joint discomfort) that limits the tolerability of high-dose rhGH. Dr. Gillett has observed in practice that patients on DAC-conjugated CJC-1295 require more frequent monitoring of IGF-1 levels and more active management of the insulin-sensitising side of the protocol than patients on pulsatile secretagogues, because the flat elevation profile removes the metabolic rest periods between GH pulses during which insulin sensitivity recovers.

“The conjugation of GHRH analogues to albumin via a reactive linker creates a long-acting compound with a pharmacokinetic profile that resembles continuous subcutaneous infusion of GHRH more closely than it resembles endogenous pulsatile secretion.”

Teichman et al., European Journal of Endocrinology, 2006

VI · Tesamorelin, the FDA-approved exception

Tesamorelin (TH9507) is a 44-amino-acid peptide that is structurally identical to the full-length human GHRH molecule with a single modification: a trans-3-hexenoic acid moiety attached to the N-terminal tyrosine residue, which extends the plasma half-life to approximately 26 to 38 minutes through reduced renal clearance and partial resistance to DPP-4 degradation. The 2010 FDA approval was for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, an indication that emerged from the recognition that HIV-associated lipodystrophy was driven in part by a relative GH deficiency that produced a metabolic syndrome-like phenotype of visceral adiposity, dyslipidemia, and insulin resistance.¹² The two key Phase 3 trials, published in 2007 and 2008 in the New England Journal of Medicine, enrolled a combined total of over 800 patients and demonstrated that 26 weeks of daily tesamorelin (2 mg subcutaneously) reduced visceral adipose tissue by approximately 15 to 18% compared to placebo, as measured by CT scan at the L4-L5 level, with a safety profile notable for a low rate of treatment-limiting adverse effects and no measurable effect on subcutaneous fat.

The relevance of these data to the off-label use of tesamorelin in non-HIV populations is both the strength and the gap in the clinical literature. The magnitude of visceral fat reduction is well-characterised, reproducible, and statistically consistent, which is more than can be said for any other GH peptide. The mechanism of that reduction (amplified GH pulsatility increasing lipolysis in visceral adipose depots, which express high levels of the GH receptor relative to subcutaneous depots) is well-understood and consistent with the known physiology of GH action on adipose tissue. The gap is that we do not have the same quality of data for non-HIV populations, and the metabolic context of HIV lipodystrophy (chronic inflammation, mitochondrial dysfunction from antiretroviral therapy, partial GH deficiency) is different enough from the metabolic context of age-related visceral adiposity that direct extrapolation requires caution.

The clinical experience reported by practitioners including Dr. Alex and Dr. Gillett suggests that tesamorelin produces meaningful visceral fat reduction in non-HIV patients when used at the same 2 mg daily dose studied in the HIV trials, with results that correlate with baseline visceral adiposity: patients with the highest baseline visceral fat see the largest absolute reductions, consistent with the receptor-level observation that GH-stimulated lipolysis is proportional to the mass of GH-responsive adipose tissue. The practical question that remains unresolved in the literature is whether tesamorelin’s visceral fat reduction in non-HIV populations is sustained after discontinuation or whether the fat returns once the lipolytic stimulus is removed, a question that applies to all lipolytic interventions and that the HIV trials did not fully answer because many patients in those studies remained on tesamorelin indefinitely.¹³

VII · How to think about combinations

The GHRH/GHRP combination framework reduces to three clinical variables: which GHRH analogue provides the desired pulse duration, which GHRP analogue provides the desired amplitude with acceptable side effects, and when in the 24-hour cycle those two molecules are administered. For a protocol designed to amplify the natural nocturnal GH pulse, the combination of unmodified CJC-1295 (as the GHRH component, with a 30- to 60-minute half-life to broaden the pulse) and ipamorelin (as the GHRP component, with minimal hunger to avoid sleep disruption) administered at bedtime is the configuration that most practitioners converge on, because it aligns the pharmacological pulse with the endogenous sleep-entrained pulse for maximum total GH secretion per night.

For a protocol designed to generate a large post-exercise GH pulse (when somatostatin tone is low and the anabolic window for GH-mediated tissue repair is open), the same combination works but the timing shifts to immediately post-training, and some practitioners substitute a faster-acting GHRP such as GHRP-2 for the ipamorelin because the hunger signal from GHRP-2 is less of a concern during the daytime when a post-training meal is anticipated anyway. The broader principle is that the GHRH component sets the pulse architecture and the GHRP component provides the amplitude, while the timing determines which endogenous GH pulse the pharmacological pulse amplifies or replaces.

The question of cycling (whether to use GH secretagogues continuously or in defined cycles with washout periods) remains unresolved in the clinical literature, and the practice varies considerably among practitioners. The argument for cycling is that continuous GHRH receptor activation may produce tachyphylaxis over months of nightly use, reducing the GH response and requiring dose escalation that partially defeats the purpose of using a secretagogue rather than rhGH. The argument against cycling is that the pulsatile secretagogues (particularly unmodified GHRH analogues) preserve the somatostatin gate, which provides natural off-periods between pulses that may prevent receptor desensitisation without the need for formal washout periods. Without published data directly comparing continuous versus cyclic administration, the clinical consensus, such as it exists, is that a five-day-on, two-day-off schedule represents a reasonable middle ground that reduces the theoretical risk of tachyphylaxis without sacrificing the consistency of GH elevation, but this is a practice pattern rather than an evidence-based recommendation.

VIII · The TRT overlap question

The relationship between androgens and the GH/IGF-1 axis runs in both directions. Testosterone administration increases GH pulse amplitude in hypogonadal men by roughly 50 to 100%, an effect that is mediated through aromatization to estradiol at the hypothalamic level, because estradiol is a potent stimulator of GHRH neuron activity in the arcuate nucleus. The clinical consequence is that a man on TRT has a higher baseline GH secretory capacity than the same man would have with hypogonadal testosterone levels, which means he may respond more strongly to a given dose of GHRH or GHRP analogue than a eugonadal or hypogonadal man would, a point that Dr. Gillett emphasises when titrating peptide doses in patients on concurrent TRT.¹⁴

The reverse interaction (GH’s effect on testosterone) is less direct but equally relevant. GH-mediated IGF-1 elevation increases Leydig cell sensitivity to luteinizing hormone, which can produce a modest increase in endogenous testosterone production in men who are not on exogenous testosterone. The effect is small (typically a 10 to 20% increase in total testosterone in eugonadal men) and is not clinically meaningful as a standalone intervention for hypogonadism, but it contributes to the overall metabolic benefit of GH secretagogues in men who have age-related declines in both GH and testosterone.

The practical concern when combining GH secretagogues with TRT is the overlapping effect on insulin sensitivity. Testosterone at replacement doses has a neutral or mildly positive effect on insulin sensitivity, but GH is a potent insulin counter-regulatory hormone, and sustained GH elevation (whether from rhGH or from a long-acting secretagogue such as DAC-conjugated CJC-1295) can produce measurable insulin resistance through GH-mediated lipolysis increasing circulating free fatty acids, which compete with glucose for oxidation in muscle tissue. The clinical mitigation is to use pulsatile secretagogues (which preserve the metabolic rest periods between GH pulses) rather than continuous GH elevation when combining with TRT, and to monitor fasting insulin and HbA1c in addition to IGF-1 when managing combination therapy, because the insulin-sensitising effect of testosterone can partially mask the insulin-resistance signal from sustained GH elevation until the metabolic cost has already accumulated.¹⁵